Why is Sobi paying $950M upfront for Arthrosi? Analyze the deal terms, the $550M in milestones, and the projected growth through the 2030s.

Colchicine use is associated with a modest reduction in the long-term risk for total joint arthroplasty (TJA) among individuals with gout, according to study findings published in Arthritis & ...

Gout, a type of inflammatory arthritis caused by a buildup of uric acid (urate) in the body, affects 5.1% of U.S. adults ...

Research shows that a common gout medication may help reduce the risk of heart attack and stroke in people with gout.

Cases of gout are rising in younger individuals, according to a global study. The condition, which is a type of inflammatory arthritis, steadily increased in people aged 15 to 39 between 1990 and 2021 ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a potential value of $1.5 billion from Swedish biopharma Sobi. Under the deal ...

James is a published author with multiple pop-history and science books to his name. He specializes in history, space, strange science, and anything out of the ordinary.View full profile James is a ...

Among patients with gouty arthritis initiating urate-lowering therapy, a single subcutaneous injection of firsekibart — an interleukin-1 beta antibody — reduced acute flares more than a daily dose of ...

The 2-time All-Star left during the 3rd quarter of Monday's OT loss to the Heat; it was unclear if the injury was an aggravation. Tim Reynolds | The Associated Press A wild sequence of events ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Frances Solá-Santiago Frances Solá-Santiago is a writer covering style. She’s ...

Atom’s lingdolinurad (ABP-671), a URAT1 inhibitor, is in late stage global clinical trials for chronic gout and ABP-745, an anti-inflammatory drug, is in multi-country Phase 2 trials for acute gout ...

Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3 trials next year. San ...